BRAF/MEK inhibitors in the treatment of malignant melanoma
Prof. MUDr. Petr Arenberger, DrSc., MBA, FCMA
Dermatovenerologická klinika 3. LF UK a Fakultní nemocnice Královské Vinohrady, Praha
Metastatic melanoma was still relatively recently considered as a malignant tumor with a very poor prognosis, with only limited response to the available treatment methods. However, over the last five years, at least in part of the patients, metastatic melanoma has been slowly changing from being a disease with poor prognosis to disease with long-term survival. It is mostly due to new therapeutic options. Ten years ago, five-year survival rate was no more than 10% of patients. Nowadays, using the latest therapeutic options, the number is approximately 30%.
metastatic malignant melanoma, BRAF inhibitors, MEK inhibitors, survival
The full article is only available to subscribers
Become a regular subscriber to our Oncological Review...